Clinical Research Directory
Browse clinical research sites, groups, and studies.
Lithium for Parkinson's: an Extension Trial
Sponsor: State University of New York at Buffalo
Summary
This study will examine the effects of 24 weeks of lithium therapy achieving serum lithium levels of 0.25-0.50mmol/L on MRI and blood-based biomarkers in Parkinson's disease patients who have completed one of our current 24-week lithium clinical trials.
Official title: Repurposing Lithium as a Disease-modifying Therapy in Parkinson's Disease: an Open-label Extension Trial.
Key Details
Gender
All
Age Range
45 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
35
Start Date
2024-08-09
Completion Date
2026-11-01
Last Updated
2025-11-19
Healthy Volunteers
No
Conditions
Interventions
Lithium aspartate
Lithium aspartate with dosage adjusted to serum lithium level 0.25-0.50mmol/L
Locations (1)
UBMD Neurology
Williamsville, New York, United States